Skandinaviska Enskilda Banken (SEB)
PBYI icon

Skandinaviska Enskilda Banken (SEB)’s Puma Biotechnology PBYI Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45,500
Closed -$467K – 1181
2020
Q4 		$467K Hold
45,500
– – ﹤0.01% 923
2020
Q3 		$459K Hold
45,500
– – ﹤0.01% 838
2020
Q2 		$474K Buy
+45,500
New +$471K ﹤0.01% 817

Other funds holding PBYI

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s PBYI Position: Q1 2021 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Puma Biotechnology (PBYI) in Q1 2021, closing a stake of 45,500 shares — an estimated $467K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in PBYI in Q2 2020 and held it in 3 quarters. The position peaked at $474K in Q2 2020. 118 funds tracked by Wall St. Rank hold PBYI as of Q1 2021.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Puma Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 45,500 Puma Biotechnology shares in Q1 2021, an estimated $467K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Puma Biotechnology in Q2 2020 and held it in 3 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Puma Biotechnology position peaked at $474K in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2021.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2021, filed 14 May 2021.